Evaluate the Efficacy and Safety of DWP05195 in Subjects With Post-Herpetic Neuralgia

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate efficacy, safety of administered DWP05195 in Postherpetic Neuralgia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daewoong Pharmaceutical Co. LTD.

Criteria

Inclusion Criteria:

• Male or Female subjects aged 20 to 80 years

• Subjects with symptoms of neuropathic pain associated with postherpetic neuralgia(PHN).

• Subjects must have pain present for > 3 months after healing of the acute herpes zoster skin rash.

Exclusion Criteria:

• Other severe pain that may potentially confound pain assessment.

• Subjects with symptoms of neuropathic pain applied Medical Equipment

• Within 2 years: Subjects were diagnosed with cancer